产品
编 号：F128766
分子式：C28H38N2O7S
分子量：546.68
分子式：C28H38N2O7S
分子量：546.68
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1345982-69-5
产品详情
生物活性：
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment.
体内研究：
Linerixibat (GSK2330672；0.05-10 mg/kg；口服强饲法；每天两次；持续 14 天；雄性 ZDF 大鼠) 处理可降低 2 型糖尿病动物模型中的葡萄糖。Animal Model:Male Zucker Diabetic Fatty (ZDF) rat
Dosage:0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:Oral gavage; twice daily; for 14 days
Result:Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin.
体外研究：
Linerixibat (化合物 56) 的两性离子、非吸湿性结晶盐形式在 pH 7.4 下显示出良好的水溶性 (>7 mg/mL)、出色的热稳定性，并且不会产生反应性或人特异性代谢物。
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment.
体内研究：
Linerixibat (GSK2330672；0.05-10 mg/kg；口服强饲法；每天两次；持续 14 天；雄性 ZDF 大鼠) 处理可降低 2 型糖尿病动物模型中的葡萄糖。Animal Model:Male Zucker Diabetic Fatty (ZDF) rat
Dosage:0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:Oral gavage; twice daily; for 14 days
Result:Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin.
体外研究：
Linerixibat (化合物 56) 的两性离子、非吸湿性结晶盐形式在 pH 7.4 下显示出良好的水溶性 (>7 mg/mL)、出色的热稳定性，并且不会产生反应性或人特异性代谢物。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备